Registry for patients with Antiphospholipid Syndrome treated with direct oral anticoagulants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to collect data on patients with Antiphospholipid Syndrome (APS) who are treated with direct oral anticoagulants (DOACs) like Rivaroxaban. The study will ensure consistency in data collection and provide safety information for non-high-risk APS patients on these medications. Participants must be at least 18 years old and have been on DOACs for a minimum of six months. The registry will help in understanding the long-term effects and safety of DOACs in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient receiving a comprehensive information about the study, and not opposed to participate
* Age ≥ 18 yo
* Classification of definite APS according to revised Sapporo-Sydney criteria
* Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months

Exclusion Criteria:

* Incomplete revised Sapporo-Sydney criteria
* No data regarding the recurrent thrombosis
* Pregnant woman
* Age \< 18 yo

Where it's running

• Stéphane Zuily
  Nancy, France Recruiting

Study contacts

• Study coordinator: Virginie Dufrost, MD, MSc
• Email: v.dufrost@chru-nancy.Fr
• Phone: +33383157828

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thromboelastometry to Predict Thrombosis and Survival in Glial Tumor Surgery

  Aimed at people with glial tumors undergoing surgery, the study tests whether thromboelastometry and other blood tests can predict blood-clot risk and survival.

  Recruiting Fundacion Clinic per a la Recerca Biomédica · Barcelona · NCT07813377

• Thrombocytopenia Trajectories in antiphospholipid syndrome

  This study tests whether patterns in platelet counts over time can predict outcomes for adults with antiphospholipid syndrome.

  Recruiting New Valley University · Al Khārjah, Kharga Oasis · NCT07757789

• Personalized blood-thinner plan for leg artery disease after repair

  A personalized plan using a blood test to tailor antiplatelet therapy is being tested against standard treatment in adults with PAD after a procedure to restore blood flow.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07613840

• Multi-omics search for clotting and bleeding markers in coronary heart disease

  This project will test whether combining proteins, metabolites, genes, sugar tags, and heart images can better predict clotting and major bleeding in people with coronary heart disease on dual antiplatelet therapy.

  Recruiting at 3 sites Chinese Academy of Medical Sciences, Fuwai Hospital · Zhengzhou, Henan and 2 other locations · NCT07523880

• Gruticibart to Prevent Catheter-Related Blood Clots

  This phase II trial tests whether a single dose of gruticibart can prevent blood clots caused by a central venous catheter in adults.

  Recruiting Phase 2 OHSU Knight Cancer Institute · Portland, Oregon · NCT07498517

• Apixaban vs Warfarin in HeartMate 3 LVAD Patients

  This study tests whether apixaban can replace warfarin to prevent clots and bleeding problems in adults with an implanted HeartMate 3 LVAD for at least 3 months.

  Recruiting Phase 3 Columbia University · New York, New York · NCT07471139

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.